Formulation Development
Lisata Therapeutics Announces US FDA Orphan Drug Designation Granted for the Treatment of Malignant Glioma
Lisata Therapeutics, Inc. recently announced the US FDA has granted Orphan Drug Designation to LSTA1, the company’s lead product candidate, for the treatment of malignant…
Recursion Bridges the Protein & Chemical Space With Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion recently announced it has successfully screened the Enamine REAL Space chemical library using its MatchMaker technology, recently acquired from Cyclica, to predict the protein target(s) for….
Comera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore Platform
Comera Life Sciences Holdings, Inc. recently announced a significant expansion of its SQore patent portfolio with the issuance of four new patents and two new…
Silo Pharma Reaches Positive Milestone With Nasal Formulation for Anxiety, PTSD & Stress-Related Disorders
Silo Pharma, Inc. recently announced it has advanced the formulation development for its therapeutic drug, SPC-15. The liquid nasal formulation will be used in….
MBX Biosciences Announces US FDA Clearance of IND Application for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for MBX 1416, the company’s long-acting glucagon-like peptide 1…
Preclinical Data Shows Strong Immunogenicity & Protection With IMUNON’s PlaCCine DNA-Based Vaccines Modality
IMUNON, Inc. recently announced a manuscript titled Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer is available…
WHITEPAPER - Addressing Regulatory Challenges for Ophthalmic Combination Products
Going forward, sponsors developing ophthalmic products formulated for delivery as eye drops must be prepared to pursue development programs that address the regulatory requirements for drug-device combination products. Partnering with a contract manufacturing organization (CMO) that has experience bringing such products to market is essential…..
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico
IGC Pharma, Inc. recently announced the addition of an important trial site at the University of Puerto Rico network as an expansion of the company’s…
Gerresheimer Expands Technical Competence Center in Wackersdorf
Gerresheimer is dedicating even more space to small batch production. It has expanded the capacity of its small-batch production (SBP) area in Wackersdorf by removing…
Sygnature Discovery Accelerates Global Growth With Major North American Acquisition
Leading integrated drug discovery partner, Sygnature Discovery, recently announced its acquisition of one of North America’s largest discovery Contract Research Organizations, Canada-based….
First Patient Enrolled in Investigator-Initiated Trial With OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema
Oculis Holding AG recently announced the first patient has been enrolled in the investigator-initiated LEOPARD trial evaluating the potential of OCS-01 eye drops, Oculis’ novel…
KBio & ZERO Announce Exclusive Strategic Alliance to Develop a Globally Distributed & Rapidly Deployable Plant-Based Molecular Farming Network
KBio and ZERO recently announced an exclusive strategic alliance to build the world’s first transportable globally distributed plant-based molecular farming network to include therapeutic, pandemic…
ProQR Therapeutics & Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen & Ultevursen Ophthalmic Assets
ProQR Therapeutics N.V. and Laboratoires Théa recently announced an agreement in which ProQR will divest its late-stage ophthalmic assets, sepofarsen and….
IntelGenx Completes Enrollment for BUENA Montelukast VersaFilm Phase 2a Clinical Trial in Patients With Mild-to-Moderate Alzheimer’s Disease
IntelGenx Corp. recently announced it has completed patient enrollment in the ongoing Montelukast VersaFilm Phase 2a (BUENA) clinical trial in patients with mild-to-moderate Alzheimer’s Disease…
Ocean Biomedical, Inc. Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day
On World Lung Cancer Day, Ocean Biomedical, Inc. is sharing details of its multi-pronged Lung Cancer Program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. He and his team have revealed that Chitinase 3-like-1 (CHi3L1) is a master regulator that inhibits….
Avenue Therapeutics Announces High Potency & Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator Supporting Phase 2 Clinical Study
Avenue Therapeutics, Inc. recently announced BAER-101, the company’s potentially best-in-class selective GABA-A α2,3 positive allosteric modulator (PAM), significantly suppressed seizures in a translational animal model…
AltruBio Announces Positive Topline Data from Phase 1 Trial of Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis
AltruBio Inc. recently announced positive topline data from its Phase 1 trial evaluating the company’s subcutaneously administered immune checkpoint enhancer (ICE), ALTB-268 in healthy volunteers. “We…
WHITEPAPER - Use of a Platform Formulation Technology to De-Risk Solid-State Variation in Drug Development
This white paper describes use of mesoporous silica as a porous carrier formulation technology to stabilize unstable polymorphs and to optimize solid state properties.
BioNTech Completes Acquisition of InstaDeep
BioNTech SE recently announced the completion of the acquisition of InstaDeep Ltd., a leading global technology company in the field of artificial intelligence (AI) and…
Bora Pharmaceuticals Unveils Eye-Opening New Facility for Ophthalmic Manufacturing
Bora Pharmaceuticals recently announce the opening of a new state-of-the-art facility in Taoyuan City, Taiwan. Officially opened by Bora Pharmaceuticals CEO Bobby Sheng and President of….
